Amgen To Webcast Investor Meeting At Upcoming American College of Cardiology's 63rd Annual Scientific Session

Amgen To Webcast Investor Meeting At Upcoming American College of Cardiology's
                        63rd Annual Scientific Session

PR Newswire

THOUSAND OAKS, Calif., March 26, 2014

THOUSAND OAKS, Calif., March 26, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will
host a webcast investor meeting at the American College of Cardiology's63rd
Annual Scientific Session (ACC.14) in Washington, D.C. on Sunday, March 30, at
7 p.m. EDT. Sean E. Harper, M.D., executive vice president of Research and
Development at Amgen, along with members of Amgen's clinical development team
and clinical investigators, will participate and discuss Amgen's
cardiovascular program, including the primary analyses of five Phase 3
evolocumab studies being presented at ACC.14.

Live audio of the investor meeting will be simultaneously broadcast over the
Internet and will be available to members of the news media, investors and the
general public.

The webcast, as with other selected presentations regarding developments in
Amgen's business given by management at certain investor and medical
conferences, can be found on Amgen's website,, under Investors.
Information regarding presentation times, webcast availability and webcast
links are noted on Amgen's Investor Relations Events Calendar. The webcast
will be archived and available for replay for at least 90 days after the

About Amgen
Amgen is committed to unlocking the potential of biology for patients
suffering from serious illnesses by discovering, developing, manufacturing and
delivering innovative human therapeutics. This approach begins by using tools
like advanced human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics
manufacturing expertise to strive for solutions that improve health outcomes
and dramatically improve people's lives. A biotechnology pioneer since 1980,
Amgen has grown to be the world's largest independent biotechnology company,
has reached millions of patients around the world and is developing a pipeline
of medicines with breakaway potential.

For more information, visit and follow us on

CONTACT: Amgen, Thousand Oaks
Wendy Woods Williams, 805-447-6382 (media)
Arvind Sood, 805-447-1060 (investors)

Amgen Logo

Logo -


Press spacebar to pause and continue. Press esc to stop.